XETRA •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:52
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeXETRA
Market Capitalization1,693.57 mln
Float304 mln
Earnings Date08/13/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
1.72
Highly suspicious
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-372
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
AtaiBeckley Inc. is a clinical-stage company focused on developing new treatments for mental health conditions, operating across the United States, Germany, and Canada. Founded in 2018 and headquartered in New York, the company is working on a broad pipeline of experimental therapies targeting conditions such as depression, anxiety, schizophrenia, and alcohol use disorder. Its drug candidates include several novel compounds that work through psychedelic and neuromodulatory pathways, with many currently in Phase 2 clinical trials.
